Experimental and Computational Investigation of the Oxime Bond Stereochemistry in c-Jun N-terminal Kinase 3 Inhibitors 11H-Indeno[1,2-b]quinoxalin-11-one Oxime and Tryptanthrin-6-oxime

Bibliographic Details
Parent link:Pharmaceutics.— .— Basel: MDPI AG
Vol. 15, iss. 7.— 2023.— Article number 1802, 20 p.
Other Authors: Matveevskaya V. V. Vladislava Vadimovna, Pavlov D. I. Dmitry Igorevich, Kovrizhina A. R. Anastasia Ruslanovna, Sukhikh T. S, Taisiya Sergeevna, Sadykov E. Kh. Evgeny Khasanovich, Dorovatovskii P. V. Pavel Vladimirovich, Lazarenko V. A. Vladimir Aleksandrovich, Khlebnikov A. I. Andrey Ivanovich, Potapov A. S. Andrey Sergeevich
Summary:Title screen
11H-Indeno[1,2-b]quinoxalin-11-one oxime (IQ-1) and tryptanthrin-6-oxime are potent c-Jun N-terminal kinase 3 (JNK-3) inhibitors demonstrating neuroprotective, anti-inflammatory and anti-arthritic activity. However, the stereochemical configuration of the oxime carbon–nitrogen double bond (E- or Z-) in these compounds was so far unknown. In this contribution, we report the results of the determination of the double bond configuration in the solid state by single crystal X-ray diffraction and in solution by 1D and 2D NMR techniques and DFT calculations. It was found that both in the solid state and in solution, IQ-1 adopts the E-configuration stabilized by intermolecular hydrogen bonds, in contrast to previously assumed Z-configuration that could be stabilized only by an intramolecular hydrogen bond
Текстовый файл
Published: 2023
Subjects:
Online Access:https://doi.org/10.3390/pharmaceutics15071802
Format: Electronic Book Chapter
KOHA link:https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=682051

MARC

LEADER 00000naa0a2200000 4500
001 682051
005 20251002115155.0
090 |a 682051 
100 |a 20251002d2023 k||y0rusy50 ba 
101 0 |a eng 
102 |a CH 
135 |a drcn ---uucaa 
181 0 |a i   |b  e  
182 0 |a b 
183 0 |a cr  |2 RDAcarrier 
200 1 |a Experimental and Computational Investigation of the Oxime Bond Stereochemistry in c-Jun N-terminal Kinase 3 Inhibitors 11H-Indeno[1,2-b]quinoxalin-11-one Oxime and Tryptanthrin-6-oxime  |f Vladislava V. Matveevskaya, Dmitry I. Pavlov, Anastasia R. Kovrizhina [et al.] 
203 |a Текст  |b визуальный  |c электронный 
283 |a online_resource  |2 RDAcarrier 
300 |a Title screen 
320 |a References: 95 tit 
330 |a 11H-Indeno[1,2-b]quinoxalin-11-one oxime (IQ-1) and tryptanthrin-6-oxime are potent c-Jun N-terminal kinase 3 (JNK-3) inhibitors demonstrating neuroprotective, anti-inflammatory and anti-arthritic activity. However, the stereochemical configuration of the oxime carbon–nitrogen double bond (E- or Z-) in these compounds was so far unknown. In this contribution, we report the results of the determination of the double bond configuration in the solid state by single crystal X-ray diffraction and in solution by 1D and 2D NMR techniques and DFT calculations. It was found that both in the solid state and in solution, IQ-1 adopts the E-configuration stabilized by intermolecular hydrogen bonds, in contrast to previously assumed Z-configuration that could be stabilized only by an intramolecular hydrogen bond 
336 |a Текстовый файл 
461 1 |t Pharmaceutics  |c Basel  |n MDPI AG 
463 1 |t Vol. 15, iss. 7  |v Article number 1802, 20 p.  |d 2023 
610 1 |a электронный ресурс 
610 1 |a труды учёных ТПУ 
610 1 |a kinase inhibitor 
610 1 |a oxime 
610 1 |a crystal structure 
610 1 |a nuclear magnetic resonance 
610 1 |a rotation barrier 
701 1 |a Matveevskaya  |b V. V.  |g Vladislava Vadimovna 
701 1 |a Pavlov  |b D. I.  |g Dmitry Igorevich 
701 1 |a Kovrizhina  |b A. R.  |c biotechnology specialist  |c Research Engineer of Tomsk Polytechnic University  |f 1995-  |g Anastasia Ruslanovna  |9 22266 
701 1 |a Sukhikh  |b T. S,  |g Taisiya Sergeevna 
701 1 |a Sadykov  |b E. Kh.  |g Evgeny Khasanovich 
701 1 |a Dorovatovskii  |b P. V.  |g Pavel Vladimirovich 
701 1 |a Lazarenko  |b V. A.  |g Vladimir Aleksandrovich 
701 1 |a Khlebnikov  |b A. I.  |c Chemist  |c Professor of Tomsk Polytechnic University  |f 1963-  |g Andrey Ivanovich  |9 17500 
701 1 |a Potapov  |b A. S.  |g Andrey Sergeevich 
801 0 |a RU  |b 63413507  |c 20251002 
850 |a 63413507 
856 4 |u https://doi.org/10.3390/pharmaceutics15071802  |z https://doi.org/10.3390/pharmaceutics15071802 
942 |c CF